Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
Summary
Targeted medicine isn’t new to lung cancer, but only a fraction of patients have the eligible mutations, such as EGFR and ALK, and thus have a chance to avoid chemotherapy and its toxic side effects. —In a Phase 3 study called IMpower110, the Roche immunotherapy atezolizumab (Tecentriq) fared better than chemotherapy in patients whose non-small cell lung cancer (NSCLC) has high levels of the protein PD-L1. —Moderna (NASDAQ: MRNA) reported encouraging Phase 1 results for cytomegalovirus and chikungunya virus infections, a small step forward for its closely watched experimental messenger RNA therapies. —Shares of Adverum Biotechnologies (NASDAQ: ADVM) fell 31 percent after what analyst Mani Foroohar of SVB Leerink called “mixed signals” in an early trial of a gene therapy for wet age-related macular degeneration. —The winners of this year’s Lasker Awards, the top US biomedical prizes, went to the inventors of the breast cancer drug Herceptin, pioneers in the field of immunology, and a nonprofit expanding global access to vaccines.
Classifications
AskAI Classifications
LabelsLinked Companies
